FDA proposes ban on semaglutide compounding

GLP-1 compounding is getting squeezed again. This time the move is more structural — not just a shortage call, but a proposal that would block large outsourcing facilities from making semaglutide, tirzepatide, and liraglutide from raw ingredients in the first place. FDA announced the proposal on April 30, 2026, and opened a public comment period that runs through June 30. ### What did FDA actually do? FDA proposed excluding semaglutide, tirzepatide, and liraglutide from the 503B bulks list — the list of active ingredients that 503B outsourcing facilities are allowed to use for office-stock compounding under federal law. FDA’s basic reasoning is simple: it reviewed the nominations and said it did not find a clinical need for outsourcing facilities to compound these drugs from bulk substances. (fda.gov) ### Why does the 503B bulks list matter? Because 503B facilities are the “mass compounding” side of the market. They can produce larger batches for clinics, med spas, and health systems, but only under specific rules. In most cases, a 503B facility cannot use a bulk drug substance unless that ingredient is on the 503B bulks list or the drug is on FDA’s shortage list at the time of compounding, distribution, and dispensing. (fda.gov) So if these GLP-1 ingredients stay off the list, that shuts a major legal pathway. ### Does this ban all compounding? No — and that’s the part people will miss if they hear “FDA bans compounded semaglutide.” This proposal is aimed at 503B outsourcing facilities using bulk ingredients. It does not automatically erase every form of compounding under every circumstance. But it does hit the channel that supported broad, scaled distribution of compounded GLP-1s. That is why the market reaction matters more than the legal wording. (fda.gov) ### Why now? Because the shortage era is ending. FDA determined tirzepatide shortage conditions were resolved on December 19, 2024, and semaglutide shortage conditions were resolved on February 21, 2025. During shortages, compounders had more room to operate. Once shortages ended, the fallback question became whether bulk compounding could continue through the 503B bulks list. FDA is now signaling that the answer is basically no. (fda.gov) ### What changes for clinics and telehealth sellers? Access gets narrower. A lot of compounded GLP-1 distribution has depended on 503B facilities supplying finished product downstream. If this proposal is finalized, clinics and telehealth companies that relied on that pipeline will have fewer options, especially for standardized office-stock supply. That does not mean every patient loses access overnight, but it does mean the easy, scalable supply chain gets harder to maintain. (wsgr.com) ### What is FDA’s argument? FDA is leaning on “clinical need,” not just brand protection. Commissioner Marty Makary said outsourcing facilities cannot lawfully compound from bulk substances when FDA-approved drugs are available unless there is a clear clinical need. The agency also framed the move as part of protecting patients and the drug approval system. In other words — if approved products exist and shortage conditions are over, FDA does not want bulk compounders acting like parallel manufacturers. (fda.gov) ### What happens next? The proposal is not final yet. FDA is taking comments through June 30, 2026, and says it will review them before making a final determination. So the immediate story is not “compounding ends today.” The real story is that FDA just put the market on notice that large-scale bulk GLP-1 compounding has a very shaky future. (fda.gov) ### Bottom line? This is FDA trying to close the door that stayed open after shortages. If the proposal sticks, compounded GLP-1s do not disappear entirely — but the bulk, outsourced version of that business gets a lot smaller. (fda.gov) (federalregister.gov)